Related Experiment Videos

Enrollment and maintenance of elderly patients in cardiovascular clinical trials

Nanette K Wenger1

  • 1Division of Cardiology, Department of Medicine, Emory University School of Medicine, 49 Jessie Hill Jr. Drive SE, Atlanta, GA 30303, USA. nwenger@emory.edu

The American Journal of Geriatric Cardiology
|November 7, 2006
PubMed

Insights

Clinical cardiovascular management for the advanced elderly is lacking evidence, leading to underuse of beneficial therapies. More research including older adults is crucial for improving their health outcomes and quality of life.

Area of Science:

  • Gerontology
  • Cardiology
  • Clinical Research

Background:

  • Cardiovascular disease (CVD) poses the greatest health burden for aged individuals.
  • Limited clinical data exists for cardiovascular management in advanced elderly populations.
  • This gap contributes to the underutilization of effective CVD therapies in older adults.

Purpose of the Study:

  • To highlight the need for more research on cardiovascular management in the advanced elderly.
  • To advocate for the inclusion of elderly individuals in clinical studies.
  • To identify key areas for research in geriatric cardiovascular care.

Main Methods:

  • This is a review article.
  • It synthesizes existing literature on cardiovascular disease in the elderly.
  • It identifies gaps in research and clinical practice.

Main Results:

  • There is a significant paucity of data guiding cardiovascular care for the advanced elderly.
  • Elderly individuals are underrepresented in clinical trials for cardiovascular interventions.
  • Current evidence does not adequately address the applicability of therapies to this demographic.

Conclusions:

  • Elderly individuals must be included in clinical research for cardiovascular preventive interventions, diagnostic procedures, pharmacotherapy, and interventional procedures.
  • Research should focus on outcomes relevant to the elderly, such as functional independence and quality of life.
  • Improved evidence is needed to optimize cardiovascular care and prolong meaningful life in the advanced elderly.

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...